原创《重组人生长激素超促排卵对卵巢反应不良患者的影响分析》：本论文主要论述了生长激素论文范文相关的参考文献,对您的论文写作有参考作用。
【摘 要】 目的 探討重组人生长激素在进行体外受精-胚胎移植（IVF-ET）超促排卵过程中对卵巢反应不良患者的影响.方法 60例进行体外受精-胚胎移植治疗的卵巢反应不良患者, 随机分为实验组和参照组, 各30例.两组均给予促性腺激素释放激素-α以及人绝经期促性腺激素（HMG）, 在此基础上实验组患者给予重组人生长激素, 参照组患者未给予重组人生长激素.对两组患者获卵数、减数分裂中期（MⅡ期）卵数、获胚数及优质胚胎数进行比较, 同时采用酶联免疫吸附试验测定血清胰岛素样生长因子Ⅰ（IGF-Ⅰ）、胰岛素样生长因子结合蛋白-3（IGFBP-3）的浓度.结果 实验组获卵数、MⅡ期卵数、获胚数及优质胚胎数均略多于参照组, 但差异无统计学意义（P>0.05）.实验组降调日、启动日及人绒毛膜促性腺激素（HCG）日的IGF-Ⅰ浓度分别为（282.98±34.75）、（280.40±34.94）、（297.08±27.36）μg/L, 均高于参照组的（264.25±34.79）、（262.67±33.34）、（271.38±32.28）μg/L, 差异有统计学意义（P<0.05）.实验组患者降调日、启动日、HCG日的血清IGFBP-3浓度均略高于参照组患者, 但差异无统计学意义（P>0.05）.结论 联合应用重组人生长激素能够有效对卵巢反应不良患者体外受精-胚胎移植的结局进行改善, 其临床机制和提升血清浓度以及改善卵子质量有显著相关的联系.
【关键词】 重组人生长激素；体外受精-胚胎移植；卵巢反应不良情况；治疗价值；效果分析
DOI：10.14163/j.cnki.11-5547/r.2017.31.053
【Abstract】 Objective To investigate the effect of recombinant human growth hormone on patients with poor ovarian response during process of superovulation in in vitro fertilization and embryo traner （IVF-ET）. Methods A total of 60 patients with poor ovarian response treated with in vitro fertilization and embryo traner were randomly divided into experimental group and control group, with 30 cases in each group. Both groups received gonadotropin releasing hormone-α and human menopausal gonadotropin （HMG）, and the experimental group also received recombinant human growth hormone. The control group received no recombinant human growth hormone. Comparison were made on number of oocytes obtained, number of ovum in the middle stage of meiosis （stage MⅡ）, number of embryos obtained and number of high-quality embryos. Serum insulin-like growth factorⅠ（IGF-Ⅰ） and insulin-like growth factor binding protein -3 （IGFBP-3） were measured by enzyme linked immunosorbent assay （ELISA）. Results The experimental group had a little more number of oocytes obtained, stage MⅡ ovum and high-quality embryos than the control group, but the difference was not statistically significant （P>0.05）. The experimental group had concentration of IGF- I at decreased day, start day and human chorionic gonadotropin （HCG） day respectively as （282.98±34.75）, （280.40±34.94） and （297.08±27.36） μg/L,
which were all higher than （264.25±34.79）, （262.67±33.34） and （271.38±32.28） μg/L in the control group, and their difference was statistically significant （P<0.05）. The experimental group had a little higher concentration of serum IGFBP-3 at decreased day, start day and HCG day than the control group, but the difference was not statistically significant （P>0.05）. Conclusion Application of recombinant human growth hormone can effectively improve the outcomes of in vitro fertilization and embryo traner in patients with poor ovarian response, and its clinical mechani is significantly related to the promotion of serum concentration and the improvement of ovum quality.
生长激素论文参考资料：
结论：重组人生长激素超促排卵对卵巢反应不良患者的影响分析为关于对不知道怎么写生长激素论文范文课题研究的大学硕士、相关本科毕业论文生长激素论文开题报告范文和文献综述及职称论文的作为参考文献资料下载。
